Cullinan Therapeutics, Inc.
CGEM- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001789972
In the last 90 days, Cullinan Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 183 institutions reported holding it in 13F filings for Q2 2026, worth $1.30B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Cullinan Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 3 filings
- 1 insider, $922.9K in total
- Insiders trading
- 1
- Net value
- −$922.9K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Cullinan Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Michaelson Jennifer | Chief Scientific Officer | 158,844 | Sep 10, 2026 | 15 |
| Sumer Jacquelyn L | Chief Legal Officer | 130,559 | Jul 2, 2026 | 5 |
| Fenton Mary Kay | Chief Financial Officer | 127,921 | Jul 2, 2026 | 4 |
| Thistle Mary | Director | – | Jun 18, 2026 | 1 |
| Allen Andrew R | Director | – | Jun 18, 2026 | 1 |
| Webster Stephen W | Director | – | Jun 18, 2026 | 1 |
| Rosenberg Anthony | Director | – | Jun 18, 2026 | 1 |
| Meek David D. | Director | – | Jun 18, 2026 | 1 |
| Doyle Mittie | Director | – | Jun 18, 2026 | 1 |
| Ahmed Nadim | President and CEO | 390,803 | Feb 25, 2026 | 4 |
| Jones Jeffrey Alan | Chief Medical Officer | 159,968 | Feb 25, 2026 | 4 |
| Savill Corrine | Chief Business Officer | 240,990 | Feb 19, 2026 | 1 |
| Nichols Weston | 10% Owner | 8,963,500Indirect | Oct 30, 2025 | 3 |
| Lynx1 Capital Management LP | 10% Owner | 8,963,500Indirect | Oct 30, 2025 | 3 |
| Martin Anne-Marie | Director | – | Jun 16, 2025 | 0 |
| Ryan David P. | Director | – | Jun 16, 2025 | 0 |
| Ebeling Thomas | Director | 186,653 | Jun 11, 2024 | 0 |
| Trigilio Jeffrey | Chief Financial Officer | 133,919 | Feb 23, 2024 | 0 |
| Baeuerle Patrick | Chief Scientific Officer | 76,000 | Feb 21, 2023 | 0 |
| Biotechnology Value Fund L P | Other: See Explanation of Responses | 64,161 | Jan 19, 2023 | 0 |
| BVF Partners L P | 10% Owner | 64,161 | Jan 19, 2023 | 0 |
| BVF Inc | 10% Owner | 64,161 | Jan 19, 2023 | 0 |
| Biotechnology Value Fund II LP | Other: See Explanation of Responses | 64,161 | Jan 19, 2023 | 0 |
| Lampert Mark N | 10% Owner | 64,161 | Jan 19, 2023 | 0 |
| Biotechnology Value Trading Fund OS LP | Other: See Explanation of Responses | 64,161 | Jan 19, 2023 | 0 |
| BVF Partners OS Ltd. | Other: See Explanation of Responses | 64,161 | Jan 19, 2023 | 0 |
| BVF I GP LLC | Other: See Explanation of Responses | 64,161 | Jan 19, 2023 | 0 |
| BVF II GP LLC | Other: See Explanation of Responses | 64,161 | Jan 19, 2023 | 0 |
| BVF GP Holdings LLC | 10% Owner | 64,161 | Jan 19, 2023 | 0 |
| Jovan-Embiricos Morana | 10% Owner | 1,255,963 | Aug 4, 2022 | 0 |
| F2 Vision SCS | 10% Owner | 1,255,963 | Aug 4, 2022 | 0 |
| F2 Bioscience I 2017 Ltd | 10% Owner | 537,392 | Jun 23, 2022 | 0 |
| Gadicke Ansbert | Director | 7,648,268Indirect | Jun 23, 2022 | 0 |
| Keane Raymond T | Chief Legal Officer | 24,124 | Feb 15, 2022 | 0 |
| Zawel Leigh | See Remarks | 69,785 | Feb 15, 2022 | 0 |
| MPM BioImpact LLC | 10% Owner | 7,648,268 | Sep 20, 2021 | 0 |
| UBS Oncology Impact Fund L.P. | 10% Owner | 7,648,268 | Sep 20, 2021 | 0 |
| Oncology Impact Fund (Cayman) Management L.P. | 10% Owner | 7,648,268 | Sep 20, 2021 | 0 |
| MPM Oncology Impact Management GP LLC | 10% Owner | 7,805,483 | Aug 25, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 22, 2023 (view filing) | Dec 21 | 1 day | Michaelson JenniferChief Scientific Officer | SSale | −1.15K | $8.50 | −$9.73K | −1.3%87.6K after | |
| Dec 20, 2023 (view filing) | Dec 18 | 2 days | Michaelson JenniferChief Scientific Officer | SSale | −238 | $8.22 | −$1.96K | −0.3%88.7K after | |
| Dec 20, 2023 (view filing) | Dec 18 | 2 days | Jones Jeffrey AlanChief Medical Officer | SSale | −386 | $8.22 | −$3.17K | −0.7%58.1K after | |
| Dec 20, 2023 (view filing) | Dec 18 | 2 days | Sumer Jacquelyn LChief Legal Officer | SSale | −290 | $8.22 | −$2.38K | −0.6%45.5K after | |
| Dec 20, 2023 (view filing) | Dec 18 | 2 days | Trigilio JeffreyChief Financial Officer | SSale | −398 | $8.22 | −$3.27K | −0.5%85.8K after | |
| Dec 13, 2023 (view filing) | Dec 12 | 1 day | Trigilio JeffreyChief Financial Officer | SSale | −1.93K | $7.81 | −$15.0K | −2.2%86.2K after | |
| Dec 13, 2023 (view filing) | Dec 12 | 1 day | Michaelson JenniferChief Scientific Officer | SSale | −1.07K | $7.81 | −$8.34K | −1.2%89.0K after | |
| Jun 29, 2023 (view filing) | Jun 28 | 1 day | Ahmed NadimPresident and CEO | SSale | −759 | $11.40 | −$8.65K | −0.7%115.8K after | |
| Jun 21, 2023 (view filing) | Jun 20 | 1 day | Jones Jeffrey AlanChief Medical Officer | SSale | −387 | $12.94 | −$5.01K | −0.7%58.4K after | |
| Jun 21, 2023 (view filing) | Jun 20 | 1 day | Michaelson JenniferChief Development Officer | SSale | −238 | $12.94 | −$3.08K | −0.3%90.0K after | |
| Jun 21, 2023 (view filing) | Jun 20 | 1 day | Trigilio JeffreyChief Financial Officer | SSale | −399 | $12.94 | −$5.16K | −0.5%85.8K after | |
| Jun 21, 2023 (view filing) | Jun 20 | 1 day | Sumer Jacquelyn LChief Legal Officer | SSale | −291 | $12.94 | −$3.77K | −0.6%45.8K after | |
| Jun 14, 2023 (view filing) | Jun 12 | 2 days | Trigilio JeffreyChief Financial Officer | SSale | −319 | $13.11 | −$4.18K | −0.4%86.2K after | |
| Jun 14, 2023 (view filing) | Jun 12 | 2 days | Michaelson JenniferChief Development Officer | SSale | −176 | $13.11 | −$2.31K | −0.2%90.3K after | |
| Jun 8, 2023 (view filing) | Jun 6-7 | 2 days | Michaelson JenniferChief Development Officer | SSale | −12.0K | $12.31 | −$147.7K | −11.7%90.4K after | 2 lots10b5-1 |
| May 24, 2023 (view filing) | May 23 | 1 day | Ahmed NadimPresident and CEO | SSale | −707 | $9.15 | −$6.47K | −0.6%116.6K after | |
| May 19, 2023 (view filing) | May 18 | 1 day | Michaelson JenniferChief Development Officer | SSale | −239 | $8.76 | −$2.09K | −0.3%90.4K after | |
| May 19, 2023 (view filing) | May 18 | 1 day | Jones Jeffrey AlanChief Medical Officer | SSale | −394 | $8.76 | −$3.45K | −0.7%58.8K after | |
| May 19, 2023 (view filing) | May 18 | 1 day | Sumer Jacquelyn LChief Legal Officer | SSale | −291 | $8.76 | −$2.55K | −0.6%46.1K after | |
| May 19, 2023 (view filing) | May 18 | 1 day | Trigilio JeffreyChief Financial Officer | SSale | −399 | $8.76 | −$3.50K | −0.5%86.5K after | |
| May 16, 2023 (view filing) | May 12 | 4 days | Michaelson JenniferChief Development Officer | SSale | −193 | $8.78 | −$1.69K | −0.2%90.7K after | |
| May 16, 2023 (view filing) | May 12 | 4 days | Trigilio JeffreyChief Financial Officer | SSale | −347 | $8.78 | −$3.05K | −0.4%86.9K after | |
| Apr 26, 2023 (view filing) | Apr 25 | 1 day | Ahmed NadimPresident and CEO | SSale | −716 | $10.59 | −$7.58K | −0.6%117.3K after | |
| Apr 20, 2023 (view filing) | Apr 18 | 2 days | Jones Jeffrey AlanChief Medical Officer | SSale | −392 | $10.71 | −$4.20K | −0.7%59.2K after | |
| Apr 20, 2023 (view filing) | Apr 18 | 2 days | Trigilio JeffreyChief Financial Officer | SSale | −398 | $10.71 | −$4.26K | −0.5%87.3K after | |
| Apr 20, 2023 (view filing) | Apr 18 | 2 days | Michaelson JenniferChief Development Officer | SSale | −238 | $10.71 | −$2.55K | −0.3%90.9K after | |
| Apr 20, 2023 (view filing) | Apr 18 | 2 days | Sumer Jacquelyn LChief Legal Officer | SSale | −290 | $10.71 | −$3.11K | −0.6%46.4K after | |
| Apr 14, 2023 (view filing) | Apr 12 | 2 days | Trigilio JeffreyChief Financial Officer | SSale | −318 | $10.22 | −$3.25K | −0.4%87.7K after | |
| Apr 14, 2023 (view filing) | Apr 12 | 2 days | Michaelson JenniferChief Development Officer | SSale | −176 | $10.22 | −$1.80K | −0.2%91.1K after | |
| Mar 27, 2023 (view filing) | Mar 20 | 7 daysLate | Trigilio JeffreyChief Financial Officer | SSale | −399 | $11.32 | −$4.52K | −0.5%88.0K after | |
| Mar 27, 2023 (view filing) | Mar 20 | 7 daysLate | Jones Jeffrey AlanChief Medical Officer | SSale | −390 | $11.32 | −$4.41K | −0.7%59.6K after | |
| Mar 27, 2023 (view filing) | Mar 20 | 7 daysLate | Michaelson JenniferChief Development Officer | SSale | −238 | $11.32 | −$2.69K | −0.3%91.3K after | |
| Mar 27, 2023 (view filing) | Mar 20 | 7 daysLate | Sumer Jacquelyn LChief Legal Officer | SSale | −305 | $11.32 | −$3.45K | −0.6%46.7K after | |
| Mar 27, 2023 (view filing) | Mar 23 | 4 days | Ahmed NadimPresident and CEO | SSale | −706 | $10.51 | −$7.42K | −0.6%118.0K after | |
| Nov 29, 2022 (view filing) | Nov 25 | 4 days | Michaelson JenniferSee Remarks | SSale | −4.00K | $13.30 | −$53.2K | −7.0%53.0K after | |
| Sep 29, 2022 (view filing) | Sep 27 | 2 days | Michaelson JenniferSee Remarks | SSale | −4.00K | $12.40 | −$49.6K | −7.0%53.0K after | |
| Aug 9, 2022 (view filing) | Aug 8 | 1 day | Michaelson JenniferChief Development Officer | SSale | −1.39K | $15.01 | −$20.8K | −2.5%53.0K after | |
| Aug 4, 2022 (view filing)9:01 PM ET | Aug 2-4 | 2 days | Jovan-Embiricos Morana and 1 other10% Owner | SSale | −49.9K | $14.26 | −$711.7K | −3.8%1.26M after | 3 lots |
| Jul 26, 2022 (view filing) | Jul 25 | 1 day | Michaelson JenniferChief Development Officer | SSale | −8.00K | $14.51 | −$116.1K | −13.1%53.0K after | |
| Jul 21, 2022 (view filing) | Jul 18-19 | 3 daysLate | Savill CorrineActing Chief Business Officer | SSale | −20.0K | $15.18 | −$303.6K | −11.8%149.6K after | 2 lots |
| Jul 12, 2022 (view filing) | Jul 11 | 1 day | Savill CorrineActing Chief Business Officer | SSale | −40.0K | $13.33 | −$533.3K | −19.1%169.6K after | 2 lots |
| Jun 23, 2022 (view filing)6:47 PM ET | Jun 21-23 | 2 days | Jovan-Embiricos Morana and 1 other10% Owner | SSale | −101.9K | $12.80 | −$1.30M | −15.9%537.4K after | 3 lots |
| Jun 7, 2022 (view filing) | Jun 6 | 1 day | Ahmed NadimPresident and CEO | PPurchase | +8.09K | $12.40 | +$100.3K | New position8.09K after | |
| Jun 3, 2022 (view filing)6:24 PM ET | Jun 1 | 2 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | PPurchase | +751.4K | $11.00 | +$8.26M | New position364.2K after | 3 lots |
| May 16, 2022 (view filing)8:54 PM ET | May 12-16 | 4 days | Jovan-Embiricos Morana and 1 other10% Owner | SSale | −418.7K | $9.66 | −$4.05M | −24.3%1.31M after | 4 lots |
| May 16, 2022 (view filing)7:34 PM ET | May 12-13 | 4 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | PPurchase | +1.11M | $9.07 | +$10.1M | New position319.4K after | 5 lots |
| Apr 5, 2022 (view filing)6:45 PM ET | Apr 1 | 4 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | PPurchase | +276.0K | $10.75 | +$2.97M | +14.4%2.20M after | 2 lots |
| Oct 20, 2021 (view filing) | Oct 18 | 2 days | Michaelson JenniferSee Remarks | SSale | −4.00K | $21.42 | −$85.7K | −14.9%22.9K after | 3 lots |
| Oct 18, 2021 (view filing) | Oct 15 | 3 days | Trigilio JeffreyChief Financial Officer | SSale | −8.00K | $25.00 | −$200.0K | −78.0%2.25K after | |
| Oct 18, 2021 (view filing) | Oct 15 | 3 days | Zawel LeighSee Remarks | SSale | −19.6K | $25.00 | −$489.4K | −34.4%37.3K after |